Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by ...

Q1 2025 Earnings Call Transcript May 5, 2025 Operator: Welcome to BioNTech’s First Quarter 2025 Earnings Call. I would like ...

Detailed price information for Immuneering Corp Cl A (IMRX-Q) from The Globe and Mail including charting and trades.

Enrollment is now complete with a total of 63 patients: 10 MSS CRC patients in the monotherapy arm 53 patients in the cemiplimab combination arm consisting of 10 MSS CRC patients and 43 PD-(L) ...

Ugur Sahin; Chief Executive Officer, Member of the Management Board; Biontech SE Oezlem Tuereci; Chief Medical Office, Member of the Management Board; Biontech SE Welcome to BioNTech's first-quarter ...

For our mRNA cancer immunotherapies, we reported data from ongoing Phase 1 trial evaluating BNT116, our off-the-shelf FixVac mRNA immunotherapy candidate in combination with cemiplimab in PD-L1 ...

and as monotherapy in second-line pancreatic cancer - - Announced clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo® (cemiplimab) in ...

Clinical Trial Supply Agreement Announced with Regeneron for Libtayo (cemiplimab): In February, Immuneering announced a clinical trial supply agreement with Regeneron Pharmaceuticals for its anti ...

BioNTech to present clinical & pre-clinical data from mRNA and next-generation immuno-oncology priority programmes at AACR 2025: Mainz, Germany Saturday, April 26, 2025, 14:00 Hrs ...

Enrollment is now complete with a total of 63 patients: 10 MSS CRC patients in the monotherapy arm 53 patients in the cemiplimab combination arm consisting of 10 MSS CRC patients and 43 PD-(L) ...

MDVIP, the national leader in membership-based healthcare, today announced the addition of board-certified family physician ...